News
(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...
Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...
A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.
Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...
Both Barad and his co-panelist, Joydeep Ganguly, SVP of corporate operations at Gilead Sciences, emphasized that they see AI ...
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...
Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results